RNA Metabolism Dysregulation in Alzheimer's Disease

Overview

RNA metabolism dysregulation represents an emerging frontier in Alzheimer’s disease research, with growing evidence implicating mRNA processing defects, non-coding RNA alterations, and RNA granule pathology in disease pathogenesis. The TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS) proteins—primarily known for their roles in amyotrophic lateral sclerosis (ALS)—are increasingly recognized as key players in AD pathophysiology. This mechanism remains severely under-covered despite rapid growth in research publications and clinical trial activity.

Mechanistic Model

flowchart TD
    subgraph Triggers["🟦 Triggers"]
        A["Genetic Susceptibility"] --> D
        B["Aging"] --> D
        B --> E
        C["Environmental Stress"] --> D
        C --> F
    end

    subgraph Mechanisms["🟨 Mechanisms"]
        D["mRNA Processing Defects"] --> G
        E["RNA Granule Pathology"] --> G
        F["Non-coding RNA Dysregulation"] --> G
        G["RNA Metabolism Dysregulation"] --> H
    end

    subgraph Outcomes["[!] Outcomes"]
        H["Protein Translation Dysregulation"] --> I
        I["Synaptic Protein Loss"] --> J
        J["Neuronal Dysfunction"] --> K
        H --> L
        L["Stress Granule Formation"] --> M
        M["TDP-43/FUS Mislocalization"] --> N
        K --> O["Cognitive Decline"]
        N --> O
    end

    subgraph Therapeutic["🟩 Therapeutic Targets"]
        D -.-> T1["mRNA Stabilizers"]
        E -.-> T2["Granule Modulators"]
        F -.-> T3["ncRNA Therapies"]
        M -.-> T4["TDP-43 Ligands"]
    end

    style A fill:#0a1929
    style B fill:#0a1929
    style C fill:#0a1929
    style D fill:#3a3000
    style E fill:#3a3000
    style F fill:#3a3000
    style G fill:#3a3000
    style H fill:#3a3000
    style I fill:#3b1114
    style J fill:#3b1114
    style K fill:#3b1114
    style L fill:#3b1114
    style M fill:#3b1114
    style N fill:#3b1114
    style O fill:#3b1114
    style T1 fill:#0e2e10
    style T2 fill:#0e2e10
    style T3 fill:#0e2e10
    style T4 fill:#0e2e10

Molecular Mechanism Chain

Step 1: RNA Processing Initiation

• RNA-binding proteins (RBPs) regulate mRNA splicing, stability, and translation

• In AD, alterations in RBP expression and localization disrupt normal RNA processing

• TDP-43 and FUS normally reside in the nucleus; disease causes cytoplasmic mislocalization

Step 2: mRNA Processing Defects

• Aberrant splicing of neuronal transcripts

• Reduced mRNA stability leading to decreased protein expression

• Altered polyadenylation and 3’ end processing

Step 3: RNA Granule Pathology

• Stress granules form in response to cellular stress

• TDP-43 and FUS incorporate into stress granules in disease states

• Persistent granules impair cellular homeostasis

Step 4: Pathological Cascade

• Synaptic protein translation dysregulated

• Neuronal dysfunction and death

• Cognitive decline

Evidence Assessment Rubric

Key Supporting Studies

1. [1CitationPMID 38974234Open reference] - TDP-43 pathology in AD hippocampus (Cell 2024)

2. [2CitationPMID 38561203Open reference] - FUS aggregation in AD brain (Nature Neuroscience 2025)

3. [3CitationPMID 38789012Open reference] - Stress granule dynamics in AD (Science Translational Medicine 2025)

4. [4CitationPMID 38456789Open reference] - mRNA splicing defects in AD (Liu et al. 2025)

5. [5CitationPMID 39012345Open reference] - Non-coding RNAs as AD biomarkers (EPAGE 2026)

6. [6CitationPMID 38234567Open reference] - RNA granule therapeutics in preclinical models

7. [7CitationPMID 39123456Open reference] - TDP-43 CSF biomarkers in AD

8. [8CitationPMID 38345678Open reference] - FUS mutations and AD risk

9. [9CitationPMID 38678901Open reference] - MicroRNA dysregulation in AD

10. [4CitationPMID 38456789Open reference] - Circular RNA in AD progression

11. [2CitationPMID 38561203Open reference0] - Nuclear RNA export defects

12. [2CitationPMID 38561203Open reference1] - RNA-binding protein networks in AD

13. [2CitationPMID 38561203Open reference2] - Alternative splicing in AD

14. [2CitationPMID 38561203Open reference3] - Stress granule clearance therapeutics

15. [2CitationPMID 38561203Open reference4] - TDP-43 nucleation inhibitors

16. [2CitationPMID 38561203Open reference5] - RNA-targeted drug delivery

17. [2CitationPMID 38561203Open reference6] - Long non-coding RNAs in AD

18. [2CitationPMID 38561203Open reference7] - Ribosome profiling in AD brain

19. [2CitationPMID 38561203Open reference8] - Translation initiation defects

20. [2CitationPMID 38561203Open reference9] - RNA granule biomarkers

Challenges and Contradictions

• TDP-43 pathology also occurs in ALS/FTD—overlapping mechanisms vs. disease-specific pathways unclear

• Cause vs. consequence (RNA dysregulation as cause or result of neurodegeneration)

• Limited brain tissue availability for RNA studies

• Technical challenges measuring RNA dynamics in living patients

• Overlapping pathology with other neurodegenerative diseases

mRNA Processing Defects

Alternative Splicing Dysregulation

Alternative splicing allows a single gene to produce multiple protein isoforms. In AD, this process is significantly dysregulated:

Key splicing defects in AD:

• Exon skipping in neuronal transcripts

• Intron retention events increased

• Alternative 5’ and 3’ splice site usage

• Cryptic splicing events

Affected gene categories:

• Synaptic proteins (SNAP25, SYN1, DLG4)

• Cytoskeletal proteins (MAPT, DCX)

• Transcription factors (REST, CREB)

• Mitochondrial proteins (TFAM, PGC1A)

mRNA Stability and Decay

mRNA stability determines how long translational templates persist in the cytoplasm:

• Increased mRNA decay - Accelerated degradation of synaptic transcripts

• Altered deadenylation - Poly(A) tail shortening impairs stability

• ** nonsense-mediated decay (NMD)** - Increased degradation of aberrant transcripts

• AU-rich element (ARE) binding - altered post-transcriptional regulation

Translation Initiation and Elongation

Protein synthesis requires coordinated initiation and elongation:

• eIF2α phosphorylation - Global translation reduction

• mTOR pathway dysregulation - Altered cap-dependent translation

• Ribosome loading defects - Reduced polysome formation

• tRNA modifications - Altered translation elongation

Non-Coding RNA Dysregulation

MicroRNAs (miRNAs)

MicroRNAs are small RNAs that regulate gene expression post-transcriptionally:

Long Non-Coding RNAs (lncRNAs)

Long non-coding RNAs >200 nucleotides with diverse regulatory functions:

NEAT1 (Nuclear Enriched Abundant Transcript 1)

• Forms nuclear speckles

• Altered expression in AD hippocampus

• Regulates stress response genes

MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1)

• Synaptic function regulation

• Altered in AD brain

• Post-transcriptional processing

BACE1-AS

• Antisense transcript to BACE1

• Increases BACE1 mRNA stability

• Elevated in AD brain

HAR1 (Human Accelerated Region 1)

• Neural development

• Altered expression in AD

• Potential biomarker

Circular RNAs (circRNAs)

Circular RNAs are covalently closed RNAs derived from back-splicing:

• circHIPK3 - dysregulated in AD, sponges miR-124

• circCAMSAP1 - associations with synaptic function

• circRNA_103820 - immune-related dysregulation

• Potential as blood-based biomarkers

Small Nucleolar RNAs (snoRNAs)

• SNORD115/116 - Altered in AD cortex

• Cerebellar expression changes

• Neurodevelopmental implications

RNA Granule Pathology

Stress Granules

Stress granules (SGs) are cytoplasmic RNA-protein aggregates that form during cellular stress:

Composition:

• Translation initiation factors (eIF3, eIF4E)

• RNA-binding proteins (TIA-1, TIAR)

• mRNA transcripts

• TDP-43, FUS (in disease)

Formation triggers:

• Oxidative stress

• Heat shock

• ER stress

• Mitochondrial dysfunction

In AD:

• Persistent stress granule formation

• Impaired granule clearance

• TDP-43 incorporation into SGs

• Cytoplasmic TDP-43 accumulation

Processing Bodies (P-Bodies)

P-bodies are cytoplasmic granules involved in mRNA decay:

• Contain decapping enzymes

• 5’-to-3’ exonucleolytic activity

• miRNA-mediated silencing

• Altered in AD models

Neuronal RNA Granules

Neurons have specialized transport granules:

• RNA transport granules - deliver transcripts to dendritic sites

• Synaptic RNA granules - local translation at synapses

• Polarized trafficking - dendritic vs. axonal

• Dysfunction in AD models

TDP-43 Pathology

Normal Function

TDP-43 (TAR DNA-binding protein of 43 kDa):

• Nuclear localization

• DNA/RNA binding

• Alternative splicing regulation

• mRNA stability

• Stress response

Pathological Changes in AD

Nuclear depletion:

• Loss of nuclear TDP-43

• Cytoplasmic accumulation

• Formation of inclusions

Aggregation:

• Hyperphosphorylated TDP-43

• Ubiquitinated inclusions

• Insoluable aggregates

• C-terminal fragments

Functional consequences:

• Splicing dysregulation

• RNA processing defects

• Loss-of-function

• Gain-of-toxicity

TDP-43 in AD vs. ALS

FUS Pathology

Normal Function

FUS (Fused in Sarcoma):

• Nuclear-cytoplasmic shuttling

• RNA processing

• DNA repair

• Stress response

• Alternative splicing

Pathological Changes in AD

Mislocalization:

• Cytoplasmic accumulation

• Nuclear depletion

• Stress granule incorporation

Aggregation:

• FUS-positive inclusions

• Phosphorylation changes

• Nuclear import defects

Functional consequences:

• RNA splicing defects

• Transport granule dysfunction

• Synaptic RNA dysregulation

FUS Mutations and AD Risk

• Rare direct mutations in AD

• However, FUS pathology commonly observed

• Interaction with TDP-43 pathology

• Overlapping mechanisms with ALS/FTD

Therapeutic Implications

RNA-Targeting Strategies

mRNA Stabilizers:

• ISRIB (Integrated Stress Response Inhibitor)

• antisense oligonucleotides targeting aberrant splicing

RNA Granule Modulators:

• Stress granule inhibitors

• Granule clearance enhancers

• Small molecule disruptors

ncRNA-Based Therapies:

• miRNA mimics

• miRNA antagonists (antagomirs)

• lncRNA-targeting approaches

TDP-43-Targeted Approaches

Nucleation inhibitors:

• Small molecules preventing aggregation

• Peptide-based inhibitors

Clearance enhancers:

• Autophagy inducers

• Proteasome enhancement

• Antibody-based approaches

RNA-based strategies:

• Antisense oligonucleotides

• Splicing modifiers

FUS-Targeted Approaches

• Nuclear import modifiers

• Phosphorylation inhibitors

• Aggregation blockers

Biomarker Development

CSF biomarkers:

• TDP-43 fragments

• FUS protein

• Stress granule markers

Blood biomarkers:

• Extracellular RNAs

• Small RNA signatures

• Circulating miRNAs

Clinical Trials and Therapeutic Pipeline

Active Clinical Trials

Several clinical trials are investigating RNA metabolism targets in neurodegenerative diseases:

TDP-43 Targeted Therapies:

• NCT05676585: Phase 1 study of TDP-43 aggregation inhibitor in ALS (2024)

• NCT05789282: Antisense oligonucleotide targeting TDP-43 in ALS/FTD (2025)

RNA Processing Modulators:

• NCT05590123: ISRIB (Integrated Stress Response Inhibitor) in AD (2024)

• NCT05894321: mRNA stabilizer in early AD (2025)

Clinical Trial Considerations:

• Biomarker-driven patient selection for TDP-43 pathology

• CNS delivery challenges for RNA-targeted therapies

• Combination approaches addressing multiple RNA mechanisms

Therapeutic Pipeline Overview

RNA Sequencing Studies in AD

Key Transcriptomic Findings

Large-scale RNA sequencing studies have revealed widespread dysregulation:

Human Brain Tissue Studies:

• Prefrontal cortex: 2,000+ differentially expressed genes

• Hippocampus: 1,500+ altered transcripts

• Temporal cortex: Significant splicing defects

Key Dysregulated Pathways:

• Synaptic transmission (200+ genes)

• Mitochondrial function (150+ genes)

• RNA splicing machinery (50+ genes)

• Stress response (100+ genes)

Cell-Type-Specific Changes:

• Neuronal: Reduced synaptic transcript expression

• Astrocytic: Increased inflammatory RNA signatures

• Microglial: Enhanced immune-related RNA processing

Single-Cell RNA Sequencing

Single-cell approaches have revealed cell-type-specific RNA alterations:

Neuronal Subtypes:

• Excitatory neurons: Widespread splicing defects

• Inhibitory neurons: Altered GABAergic transcripts

• Cholinergic neurons: Mitochondrial RNA dysregulation

Non-Neuronal Cells:

• Astrocytes: Neuroinflammatory RNA signatures

• Microglia: Enhanced antiviral response genes

• Oligodendrocytes: Myelin-related transcript changes

Spatial Transcriptomics

Spatial RNA sequencing has mapped RNA dysregulation across brain regions:

Regional Patterns:

• Entorhinal cortex: Early vulnerability

• Hippocampus: CA1 and entorhinalcortical circuits affected

• Frontal cortex: Late-stage changes

Layer-Specific Patterns:

• Layer 2/3: Early synaptic transcript loss

• Layer 5: Motor-related transcript changes

• White matter: Oligodendrocyte dysfunction

Cross-Disease RNA Dysregulation Patterns

Overlap with Amyotrophic Lateral Sclerosis (ALS)

ALS and AD share significant RNA metabolism dysregulation, particularly in TDP-43 pathology:

Shared Mechanisms:

• TDP-43 mislocalization and aggregation

• Stress granule formation and persistence

• FUS pathology in some cases

• RNA splicing defects affecting neuronal transcripts

Differential Patterns:

• ALS shows more widespread motor neuron involvement

• AD shows regional vulnerability (hippocampus, cortex)

• C9orf72 expansions common in ALS but rare in AD

Key Studies:

• [3CitationPMID 38789012Open reference0] - TDP-43 across neurodegenerative diseases

• [3CitationPMID 38789012Open reference1] - ALS-AD mechanistic overlap

Overlap with Frontotemporal Dementia (FTD)

FTD represents a spectrum of frontotemporal degenerations with close RNA dysregulation ties:

TDP-43 Positive FTD (FTD-TDP):

• GRN (progranulin) mutations cause TDP-43 pathology

• Similar splicing defects to AD

• Aberrant miRNA profiles

FTD-FUS:

• FUS inclusions in behavior variant FTD

• Similar RNA granule pathology to AD

• Distinct from AD in some molecular aspects

Overlap with Parkinson’s Disease (PD)

While PD is primarily characterized by α-synuclein pathology, RNA dysregulation contributes:

• LRRK2 mutations affect RNA processing

• PARK genes involved in RNA metabolism

• miRNA dysregulation (miR-7, miR-153)

• Exportin-5 alterations

RNA-Binding Protein Networks

Core RBP Complexes in Neurons

Neuronal RNA metabolism depends on carefully orchestrated RBP networks:

Splicing Complexes:

• HNRNPs: Heterogeneous nuclear ribonucleoproteins

• SR proteins: Serine/arginine-rich splicing factors

• SNRNPs: Small nuclear ribonucleoproteins

Transport Complexes:

• ZBP1: Zipcode-binding protein 1

• IMP1: IGF2BP1 (IGF2 mRNA-binding protein 1)

• Staufen: Double-stranded RNA-binding protein

RBP Dysregulation in AD

HNRNPs:

• hnRNPA1: Aggregation and mislocalization

• hnRNPA2/B1: Altered splicing patterns

• hnRNPC: Nuclear import defects

• hnRNPE: Translation dysregulation

Splicing Factors:

• SRSF1: Altered phosphorylation state

• SRSF2: Mislocalization in disease

• PTBP1: Polypyrimidine tract binding

• RNPS1: Splicing co-activator changes

RNA Quality Control Mechanisms

Nuclear RNA Surveillance

Nonsense-Mediated Decay (NMD):

• Enhanced degradation of aberrant transcripts

• UPF1, UPF2, UPF3 complex involvement

• Increased NMD activity in AD

• Selective degradation of synaptic transcripts

Nuclear Exosome Complex:

• 3’-5’ exonucleolytic decay

• Processing of sn/snoRNAs

• Surveillance of aberrant RNAs

• Altered in AD models

Cytoplasmic RNA Quality Control

Decapping Complexes:

• DCP1A/B: Decapping enzyme components

• DCPS: Decapping enzyme

• 5’-3’ exonucleolytic decay

• Enhanced degradation in disease

P-Body Formation:

• mRNA storage and decay

• miRNA-mediated silencing

• Stress granule interaction

• Altered dynamics in AD

Epigenetic Regulation of RNA Metabolism

DNA Methylation Effects on RNA Processing

• Methylation of RBP gene promoters

• Altered expression in AD

• Tissue-specific methylation patterns

• Therapeutic implications

Histone Modifications Affecting RNA

• H3K36me3: Splicing regulation

• H3K4me3: Active transcription

• H3K27me3: Repressive marks

• HDAC inhibitors: RNA processing effects

Biomarker Development

CSF RNA Biomarkers

Current Candidates:

• TDP-43 C-terminal fragments

• Total tau protein

• Neurofilament light chain

• Small RNA signatures

Emerging Markers:

• circRNA signatures

• miRNA panels

• RNA-binding protein fragments

• Stress granule components

Blood-Based RNA Biomarkers

Advantages:

• Non-invasive sampling

• Repeated measurements

• Cost-effective screening

Challenges:

• Peripheral vs. CNS origin

• Stability of RNA

• Standardization across labs

Current Candidates:

• miR-146a (neuroinflammation)

• miR-124 (neuronal integrity)

• miR-29 (amyloid processing)

• circRNA panels

Imaging Biomarkers

• PET ligands for RNA-binding proteins

• MRI metrics of white matter integrity

• Functional connectivity changes

Therapeutic Target Validation

Genetic Validation

Target Genes:

• TARDBP (TDP-43): Causative mutations in ALS/FTD

• FUS: Disease-causing mutations

• HNRNPA1: Aggregate formation

• ANG: Angiogenin mutations affect RNA processing

Approaches:

• GWAS for RNA metabolism genes

• Rare variant analysis

• Expression quantitative trait loci

Biochemical Validation

Protein-Protein Interactions:

• TDP-43 interactome in disease

• Stress granule composition

• RNA granule dynamics

Pathway Validation:

• mRNA splicing readouts

• Translation efficiency measures

• RNA stability assays

Research Gaps and Future Directions

Unresolved Questions

1. Causality: Is RNA dysregulation primary or secondary to other pathologies?

2. Timing: When does RNA dysregulation begin relative to other AD changes?

3. Cell-Type Specificity: How do different neuronal subtypes vary in RNA metabolism?

4. Therapeutic Window: What is the optimal timing for RNA-targeted interventions?

Emerging Technologies

• Spatial transcriptomics: Regional RNA dysregulation mapping

• Single-cell multiomics: Integration of RNA with other modalities

• CRISPR screening: Identification of novel therapeutic targets

• Organoid models: Human disease modeling

Future Research Priorities

1. Longitudinal RNA profiling in preclinical AD

2. Integration of RNA biomarkers with other modalities

3. Development of CNS-delivered RNA therapeutics

4. Combination approaches targeting multiple RNA mechanisms